Nonetheless, given that VEGF, TSP-1, and PF-4 concentrations in HPS samples were significantly higher than in HPP samples obtained with all three OA regimes, it is safe to infer that OA administration does not completely abolish platelet activation during blood conditioning (provided that the extra amount of protein in HPS was platelet-derived). The gene discussed is VEGFA; the disease is Hermansky-Pudlak syndrome.